Financial Performance - Total revenue for the three months ended October 31, 2020, was $391,797, a significant increase from $82,567 in the same period of 2019, representing a growth of 374%[12] - For the nine months ended October 31, 2020, revenue reached $595,611, compared to $351,070 for the same period in 2019, marking a year-over-year increase of 69.5%[12] - Revenue from the United States for the three months ended October 31, 2020, was $155,083, compared to $82,567 in 2019, indicating an increase of approximately 88%[44] - For the three months ended October 31, 2020, the company generated revenue of $391,787, a significant increase from $82,567 in the same period of 2019, resulting in a gross profit of $163,015 compared to a negative gross profit of $23,359 in 2019[120] - For the nine months ended October 31, 2020, the company reported revenue of $595,611, up from $351,070 in the same period of 2019, leading to a gross profit of $174,963 compared to a negative gross profit of $71,809 in 2019[124] Net Loss and Improvements - The company reported a net loss of $42,569 for the three months ended October 31, 2020, compared to a net loss of $753,274 for the same period in 2019, indicating an improvement of 94.3%[12] - For the nine months ended October 31, 2020, the company reported a net loss of $680,632, an improvement from a net loss of $1,777,192 in the same period of 2019, representing a reduction of approximately 62.3%[19] - The company sustained a net loss of $42,569, or $(0.01) per share, for the three months ended October 31, 2020, a significant improvement from a loss of $753,274, or $(0.14) per share, in the same period of 2019[123] - For the nine months ended October 31, 2020, the net loss was $680,632, or $(0.12) per share, compared to a loss of $1,777,192, or $(0.33) per share, for the same period in 2019[128] Assets and Liabilities - Total assets increased to $10,079,795 as of October 31, 2020, up from $2,197,755 as of January 31, 2020, reflecting a growth of 358%[10] - Current assets rose to $323,261 as of October 31, 2020, compared to $43,181 as of January 31, 2020, representing a substantial increase of 650%[10] - The company’s total liabilities increased to $2,825,708 as of October 31, 2020, compared to $2,022,322 as of January 31, 2020, an increase of 39.7%[10] - Stockholders' equity surged to $7,254,087 as of October 31, 2020, compared to $175,433 as of January 31, 2020, indicating a growth of 4,136%[10] Cash Flow and Financing - Cash flows from operating activities showed a net cash used of $213,909, significantly improved from $776,931 in the prior year, indicating a reduction of approximately 72.5%[19] - The company ended the period with cash and cash equivalents of $193,392, up from $97,470 at the end of the previous period, reflecting an increase of approximately 98.5%[19] - The company raised $515,108 from the sale of common stock and $194,870 from notes payable during the financing activities[19] - The Company received $34,870 under the Paycheck Protection Program (PPP), which is outstanding as of October 31, 2020, with a maturity date of June 17, 2022 and an interest rate of 0.98%[67] - A minority shareholder provided additional loans totaling $275,000, which were converted into 25,000 shares of common stock, resulting in a loss on extinguishment of $12,500[68] Acquisitions and Goodwill - The acquisition of Pocono Pharmaceuticals Inc. involved a total purchase price of $6,000,000 in common stock and a promissory note of $1,500,000[26] - The acquisition of Pocono Coated Products and Active Intelligence on August 31, 2020, involved a total purchase price of $7,500,000, which included $6,000,000 in common stock and a $1,500,000 promissory note[60][63] - Goodwill recorded from the acquisition amounted to $6,467,961, with total goodwill as of October 31, 2020, reaching $8,187,196[49][63] - The net revenue from Pocono since the acquisition was $186,917, with a net profit of $30,416[64] Research and Development - The company has budgeted $5.0 million for research and development of its abuse deterrent fentanyl transdermal system, but total costs may exceed this amount[116] - The company is seeking funding through a proposed public offering to finance the development of its lead product[116] - The company has no current plans to market its own consumer products, focusing instead on contract manufacturing in the Asia region[112] - The company is exploring follow-on applications for its abuse deterrent technology in transdermal patches for other drugs[111] Legal and Regulatory Issues - The company has faced legal proceedings, including a securities fraud action against several defendants, alleging fraudulent acquisition of 1,250,000 shares of common stock[154] - The company is subject to a settlement agreement with the SEC regarding inaccurate statements in SEC filings related to FDA jurisdiction over its consumer products[162] - The company has incurred an impairment charge due to an acquisition where the intellectual property assets were not as represented[162] - The company has not scheduled a trial date for the ongoing litigation related to the fraudulent acquisition of shares[154] - The company may face challenges in establishing a distribution network and manufacturing facilities compliant with FDA regulations for any products that receive approval[159] Operational Challenges - The company has temporarily closed operations due to a lack of available cash and the impact of the COVID-19 pandemic, raising concerns about its ability to continue as a going concern for at least one year[30] - The company has suspended its product development operations due to a lack of funds, which is critical for the development of transdermal pharmaceutical systems[157] - The company is dependent on obtaining additional financing to pay off substantial debt incurred from the acquisition of Pocono Coated Products, LLC, and to resume product development operations[158]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2020 or | Nevada | 81-1118176 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | Incorporation or organization) | Identification No.) | | 121 South Orange Ave., Suite 1500, Orlando, FL | 32801 | (Address of principal executive offices) (Zip Code) Registrant's telephone number, includ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to ___________________________ Commission file number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | Nevada | 81-1118176 | | ...